Nimedine (Cilastatin Sodium, Imipenem Monohydrate)

Nimedine (imipenem/cilastatin) is used to treat serious bacterial infections across several organ systems.

• Complicated intra‑abdominal infections: provides bacterial clearance and clinical improvement in patients with perforated or postoperative peritonitis.
• Complicated urinary tract infections: eliminates pathogenic organisms causing pyelonephritis and upper urinary tract involvement.
• Skin and soft‑tissue infections: resolves cellulitis, abscesses and necrotizing infections caused by susceptible bacteria.
• Hospital‑acquired pneumonia: treats ventilator‑associated and other nosocomial pneumonias due to resistant Gram‑negative pathogens.
• Bacterial meningitis: penetrates the cerebrospinal fluid to eradicate susceptible meningitis‑causing organisms.

• Imipenem exerts its antibacterial activity by binding to penicillin‑binding proteins, inhibiting the final transpeptidation step of peptidoglycan synthesis, which weakens the bacterial cell wall and leads to lysis. Cilastatin is co‑administered to inhibit renal dehydropeptidase‑I, preventing rapid hydrolysis of imipenem and thereby maintaining therapeutic plasma concentrations. The combined formulation ensures broad‑spectrum activity against Gram‑negative, Gram‑positive and anaerobic organisms, including many β‑lactamase‑producing strains.

Like other carbapenems, Nimedine may be associated with a range of adverse reactions.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Diarrhea: may be watery and self‑limiting.
• Headache: transient and usually resolves without intervention.
• Infusion site reactions: pain, erythema or phlebitis at the injection site.
• Rash: maculopapular skin eruption.

Serious or Rare Side Effects

• Seizures: especially in patients with pre‑existing CNS disorders or high doses.
• Anaphylaxis: severe allergic reaction requiring immediate medical attention.
• Clostridioides difficile‑associated diarrhea: can be life‑threatening colitis.
• Acute renal impairment: sudden rise in serum creatinine.
• Hepatic dysfunction: elevated transaminases in rare cases.

Prior to initiating therapy, clinicians should evaluate patient‑specific factors and monitor for adverse events.

• Renal impairment: adjust dose based on creatinine clearance.
• History of seizures: use with caution and monitor neurologic status.
• Hypersensitivity: discontinue immediately if signs of allergic reaction appear.
• Concurrent valproic acid: avoid co‑administration due to risk of reduced valproate levels.
• Pregnancy and lactation: assess risk‑benefit; limited safety data are available.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Nimedine can interact with several medicines; awareness of the interaction level guides clinical decisions.

Major Interactions (Avoid)

• Valproic acid: co‑administration markedly reduces valproate concentrations.
• Probenecid: may increase imipenem levels, raising toxicity risk.
• Renal toxic drugs (e.g., aminoglycosides): additive nephrotoxicity.

Moderate Interactions (Monitor Closely)

• Diuretics: may affect electrolyte balance; monitor renal function.
• Anticoagulants (warfarin): possible alteration of INR; monitor coagulation parameters.
• Other β‑lactams: potential additive toxicity; assess clinical necessity.